204840 — GL Pharm Tech Income Statement
0.000.00%
Last trade - 00:00- KR₩96bn
- KR₩111bn
- KR₩26bn
Annual income statement for GL Pharm Tech, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 11,988 | 12,426 | 16,729 | 26,033 | 26,048 |
| Cost of Revenue | |||||
| Gross Profit | 3,311 | 3,769 | 4,877 | 8,709 | 10,307 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 14,801 | 15,398 | 18,972 | 28,749 | 27,816 |
| Operating Profit | -2,813 | -2,973 | -2,244 | -2,716 | -1,768 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3,467 | -3,842 | -832 | -3,944 | -2,332 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3,356 | -3,734 | -790 | -3,749 | -2,337 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -3,356 | -3,727 | -790 | -3,749 | -2,337 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3,356 | -3,727 | -790 | -3,749 | -2,337 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -73.5 | -69.4 | -41.3 | -65.6 | -31.6 |
| Dividends per Share |